Patent · US Active

Pharmaceutical composition comprising guttiferone F for the treatment of prostate cancer

US9408811B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

Hong Kong Baptist University · CN

Inventors

Hongxi XU · Kowloon, CN
Xin Li · Shanghai, CN
Hong Zhang · San Diego, US
Yuanzhi LAO · Sha Tin, CN
Hongsheng TAN · Sha Tin, CN
Xiaoyu Wang · Shanghai, CN
Kaixian Chen · Shanghai, CN
Zhaoxiang BIAN · Sha Tin, CN
Dajian YANG · Sha Tin, CN
Shilin Chen · Conroe, US
Aiping Lu · Kowloon, CN
Albert Sun-Chi Chan · Kowloon, CN

Key dates

Filing date	Jul 17, 2014
Grant date	Aug 9, 2016
Priority date	—
Expiry date	Aug 11, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2236/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound of formula (I):More particularly, it relates to said anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.